Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2021

View Archived Issues

New CRISPR-Cas vector designs reduce vector size and increase vector titer for HIV/AIDS treatment

Studies show NNRTI MK-8507 can be used with islatravir, levonorgestrel/ethinyl estradiol

FDA approves IND for phase I/II study of Zofin in COVID-19 long haulers

FDA clears IND for Viracta's all-oral combination regimen in EBV-positive solid tumors

Positive data reported from phase Ib study of IMT-002 in T1D with HLA-DQ8 trait

Medshine Discovery patents new KHK inhibitors for NASH

Sorrento initiates dosing in U.K. phase II study of COVI-DROPS in outpatient setting

Positive phase II data for eprenetapopt plus azacitidine in TP53 mutant MDS and AML

IRF7 and PTDSS2 are therapeutic targets in HIV-1 infection

IFM Due divulges hSTING antagonists

Tyra Biosciences presents new FGFR inhibitors

R-107 shows the ability to prevent, treat and reverse established PAH in vivo

Rheos Medicines discloses MALT1 inhibitors

Apoptosis inhibitors show promise in severe TB models

Eureka initiates phase I/II ARYA-3 study of ECT-204 in liver cancer

Dicerna provides interim data from phase I study of belcesiran in AATLD

XPB shown to regulate HIV-1 transcriptional activity

Antengene obtains HREC approval in Australia for phase I study of ATG-101 in solid tumors and NHL

Addition of CF-296 to SOC leads to enhanced antibacterial activity against MSSA and MRSA isolates

Amplia reports phase I data on AMP-945

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.